Evidence map›Paper›PMID 37810869›Full record

ArticleHeliyon2023

Hepatic encephalopathy complications are diminished by piracetam via the interaction between mitochondrial function, oxidative stress, inflammatory response, and locomotor activity.

Hossein Niknahad, Ali Mobasheri, Abdollah Arjmand, Elahe Rafiei, Sepideh Alidaee, Hadi Razavi, Sara Bagheri, Heresh Rezaei, Samira Sabouri, Asma Najibi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 5 countries.

Hossein NiknahadPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Ali MobasheriResearch Unit of Medical Imaging, Physics, And Technology, Faculty of Medicine, University of Oulu, FI-90014, Oulu, Finland.
Abdollah ArjmandDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Elahe RafieiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sepideh AlidaeePharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hadi RazaviPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Sara BagheriPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Heresh RezaeiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Samira SabouriShanxi Key Laboratory of Ecological, Animal Sciences, And Environmental Veterinary Medicine, College of Veterinary Medicine, Shanxi Agricultural University, Taigu, Shanxi, 030801, China.
Asma NajibiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Forouzan KhodaeiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Seyyed Mohammad Amin KashaniPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Mehdi OmmatiPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Reza HeidariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IRShanxi Agricultural University · CNShahid Beheshti University of Medical Sciences · IRUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: of the study: Hepatic encephalopathy (HE) is a complication in which brain ammonia (NH Purpose: It has been found that oxidative stress, mitochondrial damage, and neuro-inflammation play a fundamental role in NH Research methods: In the current study, piracetam (100 and 500 mg/kg, oral) was used in a mice model of HE induced by thioacetamide (TA, 800 mg/kg, single dose, i.p). Results: Significant disturbances in animals' locomotor activity, along with increased oxidative stress biomarkers, including reactive oxygen species formation, protein carbonylation, lipid peroxidation, depleted tissue glutathione, and decreased antioxidant capacity, were evident in the brain of TA-treated mice. Meanwhile, mitochondrial permeabilization, mitochondrial depolarization, suppression of dehydrogenases activity, and decreased ATP levels were found in the brain of the TA group. The level of pro-inflammatory cytokines was also significantly high in the brain of HE animals. Conclusion: It was found that piracetam significantly enhanced mice's locomotor activity, blunted oxidative stress biomarkers, decreased inflammatory cytokines, and improved mitochondrial indices in hyperammonemic mice. These data suggest piracetam as a neuroprotective agent which could be repurposed for the management of HE.

Indexed as

Brain injuryHepatic encephalopathyLiver failureLocomotor disturbancesPharmacotherapy

Identifiers

PMID37810869
PMCPMC10551565
OpenAlexW4387159147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.